Abstract
One major challenge in realizing cell-based therapy for treating muscle-wasting disorders is the difficulty in obtaining therapeutically meaningful amounts of engraftable cells. We have previously described a method to generate skeletal myogenic progenitors with exceptional engraftability from pluripotent stem cells via teratoma formation. Here, we show that these cells are functionally expandable in vitro while retaining their in vivo regenerative potential. Within 37 days in culture, teratoma-derived skeletal myogenic progenitors were expandable to a billion-fold. Similar to their freshly sorted counterparts, the expanded cells expressed PAX7 and were capable of forming multinucleated myotubes in vitro. Importantly, these cells remained highly regenerative in vivo. Upon transplantation, the expanded cells formed new DYSTROPHIN+ fibers that reconstituted up to 40% of tibialis anterior muscle volume and repopulated the muscle stem cell pool. Our study thereby demonstrates the possibility of producing large quantities of engraftable skeletal myogenic cells for transplantation.
Original language | English (US) |
---|---|
Pages (from-to) | 2900-2912 |
Number of pages | 13 |
Journal | Stem Cell Reports |
Volume | 16 |
Issue number | 12 |
DOIs | |
State | Published - Dec 14 2021 |
Bibliographical note
Funding Information:The authors would like to thank Robert Arpke, Christine Rohlf, Matthew Pappas, and Julia Karls for their help with animal husbandry, imaging, and discussion. The study was supported by a Regenerative Medicine Minnesota Discovery Science grant (RMM 102516 001), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR075413, R01 AR071439, and R01 AR078571), and University of Minnesota Startup and Children's Discovery-Winefest funds. The monoclonal antibodies to PAX7, embryonic MHC, MHC, MHC-I, MHC-IIa, and MHC-IIb were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa.
Funding Information:
The authors would like to thank Robert Arpke, Christine Rohlf, Matthew Pappas, and Julia Karls for their help with animal husbandry, imaging, and discussion. The study was supported by a Regenerative Medicine Minnesota Discovery Science grant ( RMM 102516 001 ), the National Institute of Arthritis and Musculoskeletal and Skin Diseases ( R01 AR075413 , R01 AR071439 , and R01 AR078571 ), and University of Minnesota Startup and Children’s Discovery-Winefest funds. The monoclonal antibodies to PAX7, embryonic MHC, MHC, MHC-I, MHC-IIa, and MHC-IIb were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa.
Publisher Copyright:
© 2021 The Authors
Keywords
- cell therapy
- muscle stem cells
- muscular dystrophy
- myogenic differentiation
- pluripotent stem cells